Poor
Needs Revision
Patient Risk:
Medium
Summary
Several core label-supported items are correct (SSRI classification, indications, dosing framework, contraindications, administration route), but multiple claims about drowsiness/percentages/studies and specific interaction details are not supported by the provided label excerpts and several dosing/timing/clinical assertions are not evidenced in the supplied text.
Category Scores
Accurate Statements
Escitalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant medication.
Label excerpt 12.2/12.1 indicates escitalopram is an SSRI with serotonergic activity.
Escitalopram is indicated for treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older.
Section 1 INDICATIONS AND USAGE: MDD in adults and pediatric patients 12 years of age and older.
Escitalopram is indicated for treatment of generalized anxiety disorder (GAD) in adults.
Section 1 INDICATIONS AND USAGE: GAD in adults.
Escitalopram is administered orally once daily, in the morning or evening, with or without food.
Section 2.3 Administration Information.
Escitalopram is contraindicated in patients taking MAOIs with escitalopram or within 14 days of stopping escitalopram.
Section 4 CONTRAINDICATIONS: MAOIs/14-day window.
Escitalopram is contraindicated in patients taking pimozide.
Section 4 CONTRAINDICATIONS: pimozide.
Escitalopram is contraindicated in patients with hypersensitivity to escitalopram (or citalopram) or inactive ingredients.
Section 4 CONTRAINDICATIONS: hypersensitivity.
Unsupported Statements
Drowsiness is a common side effect of escitalopram, affecting up to 20% of users (per the FDA).
Provided label excerpts do not contain a quantitative incidence (e.g., up to 20%) or a specific statement defining drowsiness as common with that percentage.
The exact mechanism behind escitalopram-related drowsiness is unclear.
Provided label excerpts do not discuss an unclear mechanism specifically for drowsiness.
One suggested mechanism for escitalopram-related drowsiness is that increased serotonin levels may lead to decreased production of dopamine and norepinephrine, which regulate alertness and energy.
Provided label excerpts do not provide this serotonin→dopamine/norepinephrine reduction mechanism for drowsiness.
In a study in the Journal of Clinical Psychopharmacology, 45% of patients taking escitalopram reported increased sleepiness.
Provided label excerpts do not include this study or these percentages.
In the same study in the Journal of Clinical Psychopharmacology, 21% of patients taking placebo reported increased sleepiness.
Provided label excerpts do not include this study or these percentages.
Escitalopram can cause drowsiness, especially in the first few weeks of treatment.
Provided label excerpts do not state timing ('first few weeks') for drowsiness.
Drowsiness from escitalopram usually subsides as the body adjusts to the medication.
Provided label excerpts do not describe a drowsiness course/adjustment period.
Escitalopram-induced sleepiness is described as a common side effect.
Provided label excerpts do not state that sleepiness/drowsiness is 'common' (with a frequency).
Escitalopram-induced sleepiness is often temporary and subsides as the body adjusts to the medication.
Provided label excerpts do not discuss temporary nature or adjustment-based resolution of sleepiness.
Escitalopram usually subsides within the first few weeks of treatment.
Provided label excerpts do not support this time-to-resolution claim.
Taking escitalopram in the morning is recommended to minimize the risk of drowsiness.
Provided label excerpts state morning or evening dosing but do not recommend morning specifically to reduce drowsiness risk.
Escitalopram can interact with other medications including sedatives.
Provided label interaction table excerpts do not mention 'sedatives' generally.
Escitalopram can interact with other medications including tranquilizers.
Provided label interaction excerpts do not mention 'tranquilizers' generally.
Escitalopram can interact with other medications including antihistamines.
Provided label interaction excerpts do not mention antihistamines.
Escitalopram interactions with sedating medications may exacerbate drowsiness.
While the label excerpt discusses interference with cognitive/motor performance caution, it does not provide this specific 'sedating medications may exacerbate drowsiness' interaction statement.
In a study in the Journal of Clinical Psychopharmacology, patients taking escitalopram with other sedating medications were more likely to experience increased sleepiness.
Provided label excerpts do not include this study.
A study in the Journal of Affective Disorders found that patients taking escitalopram reported a significant decrease in quality of life due to increased sleepiness.
Provided label excerpts do not include this study.
Escitalopram can interact with other antidepressants.
Provided label interaction excerpt supports serotoninergic drug combinations increasing serotonin syndrome risk, but does not support a general statement about 'other antidepressants' without specifying the relevant classes/examples from the label.
Escitalopram is primarily used to treat panic disorder.
Provided label excerpt for indications lists MDD and GAD only; 'panic disorder' is not included.
Escitalopram-induced sleepiness is often temporary and subsides as the body adjusts to the medication.
Provided label excerpts do not discuss sleepiness temporal course.
Contradictions
High
AI Statement
Escitalopram is primarily used to treat panic disorder.
Label Reference
Section 1 INDICATIONS AND USAGE lists MDD (adults and pediatric 12+) and GAD (adults) only; panic disorder is not listed.
Important Omissions
For drowsiness/cognitive effects: the label excerpt specifically cautions patients about operating hazardous machinery (including automobiles) until they are reasonably certain escitalopram does not affect ability; no such label-based counseling was provided in the AI claims.
Importance:
Moderate
For drug interaction safety: the label provided includes specific contraindications/interaction categories (e.g., MAOIs, pimozide, other serotonergic drugs) and serotonin-syndrome monitoring/avoidance; the AI claims did not align to these specific label-supported interaction categories.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Unsupported claims about incidence percentages, study results, and timing (e.g., first few weeks) could mislead risk perception. A label-contradictory indication claim (panic disorder) is the most material accuracy issue.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
Multiple claims about sleepiness incidence/studies and interaction types are not supported by the supplied FDA label excerpts, and one indication claim (panic disorder) directly conflicts with the provided indications.
Suggested Improvement
Restrict statements to label-supported indications (MDD and GAD per Section 1), remove or replace study-specific percentage claims unless present in the provided label, and align interaction/drowsiness guidance to the label-supported content (e.g., MAOI/pimozide contraindications and serotonin-syndrome precautions; machinery-operation caution).